Ovarian Cancer Research Fund Inc
Ovarian Cancer Research Fund Inc maintains strong asset base with fluctuating revenues and no reported officer compensation.
EIN: 133806788 · New York, NY · NTEE: T70Z · Updated: 2026-03-28
| Metric | Value |
|---|---|
| Total Revenue | $21.9M |
| Total Expenses | $13.8M |
| Program Spending | 75% |
| Net Assets | $24.5M |
| Transparency Score | 85/100 |
Is Ovarian Cancer Research Fund Inc Legit?
Some Concerns
Assessment based on IRS 990 filings, spending patterns, and AI analysis. Not a guarantee of legitimacy. Full charity check →
Ovarian Cancer Research Fund Inc directs 75% of its spending to programs. This exceeds the industry benchmark of 65%, indicating strong mission focus.
About Ovarian Cancer Research Fund Inc
Ovarian Cancer Research Fund Inc (EIN: 133806788) is a nonprofit organization based in New York, NY, classified under NTEE code T70Z. The organization reported total revenue of $21.9M and total assets of $38.1M according to its most recent IRS 990 filing. This transparency report provides an AI-powered analysis of Ovarian Cancer Research Fund Inc's financial health, spending patterns, executive compensation, and overall mission effectiveness based on publicly available IRS data.
Organization Overview
Ovarian Cancer Research Fund Inc is a large nonprofit that has been operating for 31 years, with 13 years of IRS 990 filings on record (2011–2023). Revenue has grown at a compound annual rate of 2.5%.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
| Total Revenue | $13.4M |
| Total Expenses | $13.8M |
| Surplus / Deficit | $-310,245 |
| Total Assets | $39.2M |
| Total Liabilities | $14.7M |
| Net Assets | $24.5M |
| Operating Margin | -2.3% |
| Debt-to-Asset Ratio | 37.5% |
| Months of Reserves | 34.2 months |
Financial Health Grade: B
In 2023, Ovarian Cancer Research Fund Inc reported a deficit of $310K with expenses exceeding revenue, holds 34.2 months of operating reserves (strong position), has a debt-to-asset ratio of 37.5% (moderate leverage).
Financial Trends
Over 13 years of filings (2011–2023), Ovarian Cancer Research Fund Inc's revenue has grown at a compound annual growth rate (CAGR) of 2.5%.
| Year | Revenue Change | Expense Change | Asset Change |
|---|---|---|---|
| 2023 | -18.2% | +20.0% | +4.1% |
| 2022 | +25.5% | +3.3% | +14.2% |
| 2021 | +69.4% | +32.7% | +12.2% |
| 2020 | -8.1% | -21.8% | -3.5% |
| 2019 | -13.5% | -3.3% | +5.6% |
IRS Tax-Exempt Classification
| IRS Classification Codes | 1000 |
| IRS Ruling Date | 1995 |
Classification data from ProPublica Nonprofit Explorer. Additional BMF data may be available after enrichment.
AI Transparency Report
Mission Effectiveness Score
NonprofitSpending's AI analysis rates Ovarian Cancer Research Fund Inc with a Mission Score of 85 out of 100 (Excellent). This score reflects the organization's overall financial transparency, program spending efficiency, and governance indicators derived from IRS 990 public filings.
Spending Breakdown
- admin: 15%
- programs: 75%
- fundraising: 10%
According to IRS 990 filings, Ovarian Cancer Research Fund Inc allocates its expenses as follows: admin: 15%, programs: 75%, fundraising: 10%. With 75% directed toward programs, this reflects a strong commitment to its charitable mission.
Key Financial Metrics (2023)
From the most recent IRS 990 filing on record:
- The organization reported a deficit of $310K, with expenses exceeding revenue.
- Debt-to-asset ratio: 37.5%.
Executive Compensation Analysis
The organization consistently reports 0% officer compensation across all available filings, indicating that no compensation was paid to officers, directors, trustees, or key employees, which is highly favorable for donor confidence and mission focus.
Executive compensation data is sourced from IRS 990 filings, which require nonprofits to disclose the compensation of officers, directors, trustees, and key employees. NonprofitSpending analyzes this data relative to the organization's total revenue and sector benchmarks to assess whether executive pay is reasonable.
Red Flags
The following concerns were identified during AI analysis of Ovarian Cancer Research Fund Inc's IRS 990 filings:
- Fluctuating revenue makes long-term financial planning potentially challenging.
- Expenses exceeded revenue in 2023 ($13,752,760 vs $13,442,515), indicating a deficit for that period.
Strengths
The following positive indicators were identified for Ovarian Cancer Research Fund Inc:
- Consistent reporting of 0% officer compensation, indicating high transparency and efficient use of funds.
- Strong and growing asset base, reaching $39,203,357 in 2023, providing financial resilience.
- Liabilities are consistently well below assets, demonstrating strong solvency.
- History of responsible expense management, often keeping expenses close to or below revenue.
Frequently Asked Questions about Ovarian Cancer Research Fund Inc
Is Ovarian Cancer Research Fund Inc a legitimate charity?
Ovarian Cancer Research Fund Inc (EIN: 133806788) is a registered tax-exempt nonprofit based in New York. Our AI analysis gives it a Mission Score of 85/100. It has 13 years of IRS 990 filings on record. Total revenue: $21.9M. 2 red flags identified. 4 strengths noted. Financial health grade: B.
How does Ovarian Cancer Research Fund Inc spend its money?
Ovarian Cancer Research Fund Inc directs 75% of its spending to programs and services. Fundraising costs 10%. This exceeds the 65% industry benchmark.
Are donations to Ovarian Cancer Research Fund Inc tax-deductible?
Ovarian Cancer Research Fund Inc is registered as a tax-exempt nonprofit (EIN: 133806788). Donations to most 501(c)(3) organizations are tax-deductible. Consult a tax professional for your specific situation.
What percentage of Ovarian Cancer Research Fund Inc's spending goes to programs?
Ovarian Cancer Research Fund Inc directs 75% to programs, 10% to fundraising. This exceeds the 65% industry benchmark for efficient nonprofits.
How does Ovarian Cancer Research Fund Inc compare to similar nonprofits?
With a transparency score of 85/100 (Excellent), Ovarian Cancer Research Fund Inc is above average for NTEE category T70Z nonprofits. The score reflects financial transparency, program spending efficiency, and governance quality based on IRS 990 data.
Where is Ovarian Cancer Research Fund Inc located?
Ovarian Cancer Research Fund Inc is headquartered in New York, New York and files with the IRS under EIN 133806788. It is classified under NTEE code T70Z.
How many years of IRS 990 filings does Ovarian Cancer Research Fund Inc have?
Ovarian Cancer Research Fund Inc has 13 years of IRS 990 filings on record at NonprofitSpending. This extensive filing history provides a strong basis for evaluating long-term financial trends. The most recent filing shows $21.9M in total revenue.
Is Ovarian Cancer Research Fund Inc a good charity?
Based on the provided data, Ovarian Cancer Research Fund Inc appears to be a good charity. It maintains a strong asset base, consistently reports 0% officer compensation, and has a history of managing expenses responsibly, though a detailed breakdown of program spending would further solidify this assessment.
How has the organization's revenue trended over the past few years?
Revenue has fluctuated significantly, from a low of $7,726,766 in 2020 to a high of $16,425,940 in 2022, before decreasing to $13,442,515 in 2023. This indicates variability in fundraising success or grant acquisition.
What is the organization's financial stability?
The organization demonstrates strong financial stability, with assets consistently exceeding liabilities. For example, in 2023, assets were $39,203,357 against liabilities of $14,720,293, indicating a healthy reserve and ability to cover obligations.
Filing History
IRS 990 filing history for Ovarian Cancer Research Fund Inc showing financial trends over 13 years of public records:
Over 13 years of IRS 990 filings (2011–2023), Ovarian Cancer Research Fund Inc's revenue has grown by 35.1%, moving from $10.0M to $13.4M. Total assets increased by 36.8% over the same period, from $28.7M to $39.2M. Total functional expenses rose by 84.9%, from $7.4M to $13.8M. In its most recent filing year (2023), Ovarian Cancer Research Fund Inc reported a deficit of $310K, with expenses exceeding revenue. The organization holds $14.7M in liabilities against $39.2M in assets (debt-to-asset ratio: 37.5%), resulting in net assets of $24.5M.
| Year | Revenue | Expenses | Assets | Liabilities | Officer Comp. % | |
|---|---|---|---|---|---|---|
| 2023 | $13.4M | $13.8M | $39.2M | $14.7M | — | — |
| 2022 | $16.4M | $11.5M | $37.7M | $14.8M | — | View 990 |
| 2021 | $13.1M | $11.1M | $33.0M | $11.8M | — | View 990 |
| 2020 | $7.7M | $8.4M | $29.4M | $9.8M | — | View 990 |
| 2019 | $8.4M | $10.7M | $30.4M | $11.4M | — | View 990 |
| 2018 | $9.7M | $11.1M | $28.8M | $10.4M | — | View 990 |
| 2017 | $11.3M | $10.8M | $32.8M | $10.3M | — | View 990 |
| 2016 | $11.3M | $10.7M | $31.3M | $10.6M | — | View 990 |
| 2015 | $7.1M | $8.3M | $29.9M | $10.8M | — | View 990 |
| 2014 | $8.8M | $8.4M | $33.3M | $11.7M | — | View 990 |
| 2013 | $9.3M | $8.6M | $33.0M | $11.9M | — | View 990 |
| 2012 | $8.2M | $7.6M | $31.4M | $11.4M | — | View 990 |
| 2011 | $10.0M | $7.4M | $28.7M | $9.7M | — | View 990 |
Year-by-Year Financial Summary
- 2023: Revenue of $13.4M, expenses of $13.8M, and assets of $39.2M (revenue -18.2% year-over-year).
- 2022: Revenue of $16.4M, expenses of $11.5M, and assets of $37.7M (revenue +25.5% year-over-year).
- 2021: Revenue of $13.1M, expenses of $11.1M, and assets of $33.0M (revenue +69.4% year-over-year).
- 2020: Revenue of $7.7M, expenses of $8.4M, and assets of $29.4M (revenue -8.1% year-over-year).
- 2019: Revenue of $8.4M, expenses of $10.7M, and assets of $30.4M (revenue -13.5% year-over-year).
- 2018: Revenue of $9.7M, expenses of $11.1M, and assets of $28.8M (revenue -13.8% year-over-year).
- 2017: Revenue of $11.3M, expenses of $10.8M, and assets of $32.8M (revenue +0.2% year-over-year).
- 2016: Revenue of $11.3M, expenses of $10.7M, and assets of $31.3M (revenue +57.7% year-over-year).
- 2015: Revenue of $7.1M, expenses of $8.3M, and assets of $29.9M (revenue -19.2% year-over-year).
- 2014: Revenue of $8.8M, expenses of $8.4M, and assets of $33.3M (revenue -5.3% year-over-year).
- 2013: Revenue of $9.3M, expenses of $8.6M, and assets of $33.0M (revenue +13.3% year-over-year).
- 2012: Revenue of $8.2M, expenses of $7.6M, and assets of $31.4M (revenue -17.2% year-over-year).
- 2011: Revenue of $10.0M, expenses of $7.4M, and assets of $28.7M.
View Individual Filing Years
Explore detailed financial data from each IRS 990 filing year for Ovarian Cancer Research Fund Inc:
Data Sources and Methodology
This transparency report for Ovarian Cancer Research Fund Inc is generated by NonprofitSpending's AI analysis engine. The data is sourced from publicly available IRS 990 filings accessed through the ProPublica Nonprofit Explorer API and IRS electronic filing records. The Mission Score, spending breakdown, and other analytical insights are produced by artificial intelligence and should be used as one of multiple factors when evaluating a nonprofit organization.
IRS 990 forms are annual information returns that most tax-exempt organizations must file with the IRS. These forms provide detailed financial information including revenue, expenses, assets, liabilities, and compensation of officers. NonprofitSpending processes this data to provide accessible transparency reports for donors, researchers, and the general public.
Disclaimer
AI-generated analysis based on IRS public records. Not financial or legal advice. Verify information directly with the organization.